The Sri Madhusudan Sai Institute (SMSIMSR) has been awarded a ₹5.5 crore ICMR grant to pioneer affordable diagnostics and precision therapies for Epidermolysis Bullosa (EB) in India.

  • SMSIMSR received a ₹5.5 crore research grant from ICMR.
  • The 4-year project is titled 'ADAPT-EB'.
  • Focus: Developing affordable diagnostics and precision treatments for Epidermolysis Bullosa (EB).
  • Target: Reducing diagnostic costs by over 60% via low-cost genomic assays.

In a significant boost to medical research in India, the Sri Madhusudan Sai Institute of Medical Sciences and Research (SMSIMSR), located in Muddenahalli, Chickballapur district, Karnataka, has secured a massive ₹5.5 crore research grant from the Indian Council of Medical Research (ICMR). The funding is dedicated to tackling Epidermolysis Bullosa (EB), a rare and debilitating genetic skin disorder.

The grant, amounting to ₹5,50,08,874, is awarded for a duration of four years to support the ADAPT-EB project (Developing Accessible Diagnostics and Affordable Precision Therapies for Epidermolysis Bullosa in the Indian population). The research initiative will be spearheaded by Dr. Vamsi Krishna Yenamandra, alongside co-investigators Dr. Divya Seshadri, Dr. Manoj Srinivasa, and Dr. Sharath Chandra Konda.

Read Also:H1N1 Surge: IMA Urges Caution and Warns Against Self-Medication

Understanding Epidermolysis Bullosa (EB)

Epidermolysis Bullosa is a complex group of inherited disorders characterized by extreme skin fragility. Even minor friction or trauma can result in severe blistering and open wounds. Patients suffering from EB often face chronic wounds, significant scarring, nutritional complications, and a heightened risk of developing skin cancer. Currently, India lacks a national EB registry, and access to specialized multidisciplinary care remains a significant challenge for many families.

Why This Matters

BozokMedia analysis shows that this project addresses a critical gap in the Indian healthcare ecosystem: the lack of affordable molecular diagnostics for rare genetic conditions. By focusing on localized, low-cost solutions, this research could democratize access to life-altering medical technology.

"ADAPT-EB is designed to address the gap where specialized diagnosis and care are difficult to access for patients and families." - Dr. Yenamandra

A primary objective of the ADAPT-EB project is to develop low-cost targeted genomic assays. These innovations are expected to reduce diagnostic expenses by more than 60% compared to traditional whole-exome sequencing methods. Furthermore, the research team will investigate 'revertant mosaicism'—a natural genetic self-correction process—to explore its potential in creating patient-specific regenerative therapies.

The project aims to integrate prevention, prediction, diagnosis, and genotype-guided disease management into a single, cohesive framework, ultimately improving genetic counseling and therapeutic accessibility across the country.

Did You Know?: Epidermolysis Bullosa is often colloquially referred to as 'Butterfly Skin' because the skin is as delicate as a butterfly's wings.

Frequently Asked Questions

1. What is the main goal of the ADAPT-EB project?
The goal is to develop accessible diagnostics and affordable precision therapies for Epidermolysis Bullosa specifically for the Indian population.

2. How will this project affect diagnostic costs?
Through new genomic assays, the project aims to reduce the cost of diagnosis by more than 60%.